Prosecution Insights
Last updated: April 19, 2026

Leason Ellis LLP (Tonix)

6 pending office actions • 2 clients

Portfolio Summary

6
Total Pending OAs
1
Final Rejections
5
Non-Final OAs

Client Portfolio (2 clients)

Client (Assignee)Pending OAs
Tonix Pharma Limited 4
Tonix Pharma Limited 2

Pending Office Actions

App #TitleClientExaminerArt UnitStatusFiled
18271098 METHODS OF INDUCING IMMUNE TOLERANCE WITH MODIFIED ANTI-CD154 ANTIBODIES Tonix Pharma Limited TAYLOR, LIA ELAN 1641 Non-Final OA Jul 06, 2023
18212500 CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC) Tonix Pharma Limited BARSKY, JARED 1628 Non-Final OA Jun 21, 2023
18265525 CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA Tonix Pharma Limited CHONG, YONG SOO 1623 Non-Final OA Jun 06, 2023
17638761 MODIFIED TFF2 POLYPEPTIDES Tonix Pharma Limited LIEB, JEANETTE M 1654 Non-Final OA Feb 25, 2022
17226058 CYCLOBENZAPRINE TREATMENT FOR SEXUAL DYSFUNCTION Tonix Pharma Limited CRAIGO, WILLIAM A 1615 Final Rejection Apr 08, 2021
17269106 METHODS OF TREATING ACUTE STRESS DISORDER AND POSTTRAUMATIC STRESS DISORDER Tonix Pharma Limited BAEK, BONG-SOOK 1611 Non-Final OA Feb 17, 2021

Managing Leason Ellis LLP (Tonix)'s Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month